There are almost one million people with dementia in the UK and the most common cause is Alzheimer’s disease. Researchers from University College London (UCL) with funding from the National Institute for Health and Care Research are testing a new approach to the treatment of mild Alzheimer’s disease in the DESPIAD (DEpletion of SaP in […]

After a period of many online studies, we are pleased to share that researchers are increasingly inviting participants to take part in face to face studies.  Here are some examples of studies currently looking for volunteers to take part in different parts of the UK: Sleep, gut health and cognition study Insomnia in later life […]

Alzheimer’s disease is the most common cause of dementia in the UK and the symptoms develop gradually over many years. Background The symptoms of Alzheimer’s disease can progress slowly and many, such as getting more forgetful, can be attributed to ‘just getting older.’ This can make diagnosis more difficult and currently there is no single […]

All medicines may have side effects for the people who take them. But if there was a new treatment to slow or stop Alzheimer’s, how would you weigh up its benefits against its potential risks? That’s what researchers are asking as part of a new project. One of our charity partners, Alzheimer’s Research UK, has […]

An opinion piece by Professor John O’Brien, NIHR Clinical Research Network National Specialty Lead for Dementias The European Medicines Agency (EMA) has today said no to approving aducanumab – a new drug to treat Alzheimer’s disease. EMA considered that although the drug removed amyloid, a toxic protein that builds up in the brains of people […]

The possible link between air pollution and dementia has been a focus of several studies and at the recent US Alzheimer’s Association International Conference (AAIC), the topic came to the fore again.  New findings Whilst previous reports have linked long-term air pollution exposure with accumulation of Alzheimer’s disease-related brain plaques, a series of new reports […]

The US Food and Drug Administration (FDA) has this week approved the first drug since 2003 to treat Alzheimer’s disease. Aducanumab, created by US pharmaceutical company Biogen, is an antibody designed to target amyloid, a protein that builds up in the brains of people with early stages of Alzheimer’s disease. Whereas other existing treatments help […]

It is well documented that music and singing are beneficial to those living with dementia. Listening to or singing songs can provide both behavioural and emotional benefits and the power of music can unlock memories and help provide links to a person’s past and promote connection with carers. Researchers at Nottingham University are looking for […]

Alzheimer’s disease affects approximately 70% of people diagnosed with dementia, and an estimated 26 million people worldwide. In the very early stages, Alzheimer’s disease may be referred to or diagnosed as Mild Cognitive Impairment (MCI). There are no available treatments to prevent or delay the start of Alzheimer’s disease and currently medications only provide a […]

As we turn six today, we are celebrating not only six years of bringing researchers and volunteers together, but also our collective achievement of helping dementia research to keep going during the pandemic.   See what our volunteers, charity partners and researchers have to say about us!   Since Join Dementia Research began, an incredible […]